Home » Stocks » HAE

Haemonetics Corporation (HAE)

Stock Price: $113.84 USD -5.28 (-4.43%)
Updated Jan 27, 2021 11:05 AM EST - Market open
Market Cap 6.14B
Revenue (ttm) 902.53M
Net Income (ttm) 106.15M
Shares Out 50.70M
EPS (ttm) 2.07
PE Ratio 54.94
Forward PE 36.10
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $113.84
Previous Close $119.12
Change ($) -5.28
Change (%) -4.43%
Day's Open 117.07
Day's Range 112.99 - 117.82
Day's Volume 224,550
52-Week Range 74.34 - 129.03

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 21 hours ago

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 5 days ago

BOSTON, Jan. 22, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics"), a global medical technology company focused on delivering innovative medical solutions to drive bette...

PRNewsWire - 1 week ago

BOSTON, Jan. 20, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics"), a global medical technology company focused on delivering innovative medical solutions to drive bette...

Zacks Investment Research - 1 week ago

Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.

PRNewsWire - 3 weeks ago

BOSTON, Jan. 5, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2021 financial results at 6:00 am EDT on Tuesda...

Forbes - 1 month ago

With the Covid vaccine rollout accelerating, these companies will be big beneficiaries in the year ahead.

Other stocks mentioned: CNNWF, ICAGY, SSEZY, VMC
Seeking Alpha - 1 month ago

Haemonetics has sustainable growth levers in place that are underscored by key product offerings and recent liquidity preservation measures. The company remains insulated from larger names via...

Zacks Investment Research - 1 month ago

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

Forbes - 1 month ago

We believe that Haemonetics stock, best known for its blood and plasma supplies and services, is a good buying opportunity at the present time. HAE stock trades near $113 currently and it is, ...

Zacks Investment Research - 1 month ago

Haemonetics (HAE) invests in clinical trials that build evidence for its hemostasis management products.

Insider Monkey - 2 months ago

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking ...

Zacks Investment Research - 2 months ago

Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.

Seeking Alpha - 2 months ago

Haemonetics Corporation (HAE) CEO Chris Simon on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Haemonetics (HAE) delivered earnings and revenue surprises of 24.00% and 3.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 months ago

  Shares of Haemonetics (NYSE:HAE) fell 0.1% in pre-market trading after the company reported Q2 results.

PRNewsWire - 2 months ago

BOSTON, Nov. 4, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal 2021, which ended September 26, 2020, are available on it...

Zacks Investment Research - 2 months ago

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 3 months ago

BOSTON, Oct. 6, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2021 financial results at 6:00 am EDT on Wednes...

PRNewsWire - 3 months ago

BOSTON, Oct. 2, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outc...

24/7 Wall Street - 3 months ago

With the third quarter of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the stretch run of the year and at wha...

Other stocks mentioned: CI, HZNP, VRTX, BTAI
PRNewsWire - 4 months ago

BOSTON, Sept. 9, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcar...

Zacks Investment Research - 4 months ago

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

Market Watch - 5 months ago

Shares of blood transfusion and plasma provider Haemonetics Inc. HAE, +2.34% were off their highs on Monday, after Needham analysts said news of an emergency use authorization for convalescent...

Seeking Alpha - 5 months ago

Haemonetics Corporation (HAE) CEO Chris Simon on Q1 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

BOSTON, Aug. 7, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outc...

Zacks Investment Research - 5 months ago

Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.

Zacks Investment Research - 5 months ago

Haemonetics (HAE) delivered earnings and revenue surprises of 12.20% and 1.35%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of Haemonetics (NYSE:HAE) moved higher by 0.1% in pre-market trading after the company reported Q1 results.

Zacks Investment Research - 5 months ago

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 6 months ago

BOSTON, July 24, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient out...

24/7 Wall Street - 6 months ago

Increasingly, the Wall Street firms we cover agree that while the future is still bright for the U.S.

Other stocks mentioned: AMGN, MRNA, NFLX
PRNewsWire - 6 months ago

BOSTON, July 6, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2021 financial results at 6:00 am EDT on Tuesday...

PRNewsWire - 6 months ago

BOSTON, June 30, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient out...

24/7 Wall Street - 7 months ago

With the first half of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the second half of the year, with what sh...

Other stocks mentioned: AMED, BMRN, HZNP, ZBH
Zacks Investment Research - 7 months ago

Investors continue to be optimistic about Haemonetics (HAE) on sustained underlying product demand and geographical expansion.

Zacks Investment Research - 7 months ago

Haemonetics (HAE) inks deal to enhance operations and provide high quality products through an asset-lite approach in its blood filters operations.

PRNewsWire - 7 months ago

BOSTON, June 3, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outc...

Forbes - 7 months ago

Boston Scientific, best known for its products in interventional medical specialties, has seen its stock price grow roughly 50% in the last few years. In comparison, Haemonetics, one of the wo...

Other stocks mentioned: BSX
PRNewsWire - 7 months ago

BOSTON, May 28, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outc...

Seeking Alpha - 8 months ago

Haemonetics's (HAE) CEO Chris Simon on Q4 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.

Zacks Investment Research - 8 months ago

Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 8 months ago

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Other stocks mentioned: DXCM, PRGO
Zacks Investment Research - 9 months ago

Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 9 months ago

Haemonetics (HAE) expands its portfolio with the buyout of enicor. With the latter's whole blood coagulation testing system, the company will address a wider range of criticalities in medicine.

Zacks Investment Research - 9 months ago

Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 10 months ago

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 10 months ago

Haemonetics (HAE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 11 months ago

Haemonetics (HAE) witnesses high investor confidence on solid prospects.

About HAE

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides au... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
May 9, 1991
CEO
Christopher Simon
Employees
3,004
Stock Exchange
NYSE
Ticker Symbol
HAE
Full Company Profile

Financial Performance

In 2019, Haemonetics's revenue was $988.48 million, an increase of 2.16% compared to the previous year's $967.58 million. Earnings were $76.53 million, an increase of 39.09%.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Haemonetics stock is "Buy." The 12-month stock price forecast is 142.67, which is an increase of 25.33% from the latest price.

Price Target
$142.67
(25.33% upside)
Analyst Consensus: Buy